Heart Failure Trial Enrollees Atypical, Study Shows MedPage Today The patients who participated in the RELAX-AHF trial of serelaxin for acute heart failure were not representative of the larger heart failure population, researchers found. Only 20.7% of patients from a real-world U.S. registry and 16.2% of those from ... |
